Beijing Tiantan Biological Products (SHSE:600161) Cash-to-Debt : 112.48 (As of Mar. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Beijing Tiantan Biological Products Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Beijing Tiantan Biological Products's cash to debt ratio for the quarter that ended in Mar. 2024 was 112.48.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Beijing Tiantan Biological Products could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Beijing Tiantan Biological Products's Cash-to-Debt or its related term are showing as below:

SHSE:600161' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.22 Med: 4.64 Max: No Debt
Current: 112.48

During the past 13 years, Beijing Tiantan Biological Products's highest Cash to Debt Ratio was No Debt. The lowest was 0.22. And the median was 4.64.

SHSE:600161's Cash-to-Debt is ranked better than
79.04% of 1493 companies
in the Biotechnology industry
Industry Median: 6.89 vs SHSE:600161: 112.48

Beijing Tiantan Biological Products Cash-to-Debt Historical Data

The historical data trend for Beijing Tiantan Biological Products's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Beijing Tiantan Biological Products Cash-to-Debt Chart

Beijing Tiantan Biological Products Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

3.53

2.07

8.51

9.21

107.51

Beijing Tiantan Biological Products Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															10.16	10.68	22.92	107.51	112.48

Competitive Comparison of Beijing Tiantan Biological Products's Cash-to-Debt

For the Biotechnology subindustry, Beijing Tiantan Biological Products's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beijing Tiantan Biological Products's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Tiantan Biological Products's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Beijing Tiantan Biological Products's Cash-to-Debt falls into.

Beijing Tiantan Biological Products Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Beijing Tiantan Biological Products's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4554.949	/	(17.951	+	24.415)
	=	107.51

Beijing Tiantan Biological Products's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4748.889	/	(14.71	+	27.51)
	=	112.48

Beijing Tiantan Biological Products (SHSE:600161) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Beijing Tiantan Biological Products Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Beijing Tiantan Biological Products's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Tiantan Biological Products (SHSE:600161) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Tiantan Biological Products Corp Ltd (SHSE:600161) » Definitions » Cash-to-Debt

Traded in Other Exchanges

N/A

Address

No. 4 Sanjianfang South Li, Zhongdan Center, Beijing, CHN, 100024

Website

http://www.tiantanbio.com

Beijing Tiantan Biological Products Corp Ltd is a China-based company engaged in the research and development, manufacturing, sales and consulting services for blood products. The company's blood products include Shanghai Blood Human Albumin, Shanghai blood system intravenous injection of human immunoglobulin, Guizhou blood human albumin, Rongsheng human albumin, Guizhou blood system static injection immunoglobulin, Rongsheng tetanus human immunoglobulin and others.

Executives

Wang Jian Ming	Supervisors
Liu Ya Na	Directors, senior managers
Fu Dao Xing	Directors, senior managers
He Yan Lin	Directors, senior managers
Hu Li Gang	Director
Ci Xiang	senior management
Yang Hui Chuan	Director
Zhang Yi	senior management
Wu Zhen Shan	senior management

Beijing Tiantan Biological Products (SHSE:600161) Headlines

No Headlines